Table 3.

Variables associated with transplant outcome

	N	Death N	2-year OS (95% CI)	Relapse N	2-year CIR (95% CI)
Remission status at BMT1
Non-CR1	4	3	25% (1–67%)	2	50% (0–100%)
CR1	21	2	88% (60–97%)	5	34% (8–60%)
Conditioning intensity1,2
Ablative	22	3	83% (56–94%)	4	26 (3–49%)
Reduced	3	2	NA (NA)	3	NA (NA)
TBI containing conditioning1
No	10	4	53% (17–79%)	5	56% (19–93%)
Yes	15	1	92% (54–99%)	2	19% (0–45%)
Induction type2
ALL-type	8	3	43% (6–78%)	5	NA (NA)
AML-type	17	2	87% (58–97%)	2	15% (0–36%)
MPAL Subtype2 *
B/Myeloid	8	1	83% (27–98%)	0	0% (0–0%)
T/Myeloid	7	0	100% (100–100%)	3	49% (3–94%)
Ph+ MPAL	5	2	60% (13–88%)	1	20% (0–60%)
MLL MPAL	4	2	50% (6–85%)	3	NA (NA)
Age (years)
≥18	21	3	83% (55–94%)	5	32% (7–58%)
<18	4	2	50% (6–85%)	2	50% (0–100%)
Diagnostic WBC2
≤13.5x10^9/L	10	0	100% (100–100%)	0	0% (0–0%)
>13.5x10^9/L	11	5	80% (39–95%)	4	49% (10–89%)
Cytogenetics
No complex karyotype	16	3	77% (44–92%)	4	29% (3–55%)
Complex karyotype	9	2	76% (33–94%)	3	51% (3–99%)
No monosomy	20	4	74% (44–90%)	4	26% (2–49%)
Monosomy	5	1	80% (20–97%)	3	60% (6–100%)
GVHD prophylaxis
Non-TCD	13	2	82% (44–95%)	5	48% (13–83%)
TCD	12	3	69% (30–89%)	2	22% (0–51%)
Donor
HLA Mismatched	10	2	73% (28–93%)	1	11% (0–33%)
HLA Matched	15	3	77% (44–92%)	6	50% (19–80%)
Cell source
Peripheral blood or bone marrow	19	5	69% (40–86%)	7	44% (18–69%)
Cord blood	6	0	100% (100–100%)	0	0% (0–0%)
MRD at time of transplant
No	13	4	65% (31–86%)	3	26% (0–54%)
Yes	9	0	100% (100–100%)	1	25% (0–74%)

¹A significant variable in OS;

²A significant variable in relapse.

^#Ablative conditioning was busulfan based (n=4); clofarabine, melphalan and thiotepa (n=2); TBI based (n=9); or other.

^*One patient with NOS MPAL was not included in the survival analysis.

CIR: Cumulative incidence rate; NA: not available; MRD: minimal residual disease, TBI: total body irradiation.